Stock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue

Stock Track

06/24

Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.

The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.

Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/1120285849"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120285849\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120285849?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 10:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120285849","market":"nz","top_or_hot":-1,"title":"Stock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue","media":"Stock Track","content":"<p>Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.</p><p>The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.</p><p>Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Telix Pharmaceuticals Soars 9.62% Intraday on Strong Pipeline and Commercial Imaging Revenue\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-06-24 10:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.</p><p>The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.</p><p>Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TLX.AU","symbol_name":"TELIX PHARMACEUTICALS LTD","start_time":0,"source_url":"","article_id":"1120285849","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120285849","pubTimestamp":1782269074,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TLX.AU":"TELIX PHARMACEUTICALS LTD"},"translate_title":"个股赛道|Telix Pharmaceuticals盘中飙升9.62%，得益于强劲的管线和商业影像收入","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1},"content_text":"Telix Pharmaceuticals Ltd (ASX:TLX) saw its stock price surge 9.62% during intraday trading on Wednesday.The company, which develops radiopharmaceutical imaging agents and therapies for cancers, is generating significant revenue from its commercial Precision Medicine segment, with products like Illuccix and Gozellix in use across major markets. Investors appear optimistic about its late-stage therapy pipeline, including Phase 3 programs TLX591 and TLX101-Tx, which target long-term treatment revenue.Further positive sentiment may stem from the company's collaborations with partners like Regeneron and United Imaging, as well as its current valuation trading on lower price-to-sales multiples compared to many Australian biotech peers, presenting a potential value opportunity.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}